Stelios Tzellos | How Haematology Changed the Way Pharma Thinks About Cancer Markets

Stelios Tzellos

Ten years ago, most pharmaceutical market reports treated haematological cancers as a niche within oncology. The patient populations were smaller. The treatment options were limited. And the commercial teams that covered solid tumors rarely spent time thinking about lymphomas or leukaemias. That changed fast.

Today, haematology represents some of the most commercially significant oncology markets in the industry. CAR-T therapies, bispecific antibodies, and targeted small molecules have turned what were once underserved indications into fierce competitive battlegrounds. Stelios Tzellos of the UK has been working across haematology and oncology analytics since the beginning of that shift.

When the Niche Became the Frontline

Tzellos began his pharmaceutical career at GlobalData as a healthcare analyst focused on oncology and haematology. He produced market forecasts and competitive assessments for indications including Hodgkin's lymphoma. At the time, haematology was already starting to attract pipeline investment, but the commercial infrastructure hadn't caught up.

The challenge was that haematological cancers don't behave like solid tumors from a market perspective. Patient populations are fragmented by subtype. Treatment sequencing is complex. And the pace of clinical development in areas like multiple myeloma and leukaemia meant that competitive fields could shift between the time a forecast was built and the time it was presented to leadership.

That volatility required a different kind of analyst: someone who could read the clinical pipeline, understand the biological mechanisms behind each new therapy, and translate that into a commercial projection that wouldn't be obsolete in six months.

What Haematology Taught the Rest of Oncology

Haematology was, in many ways, the testing ground for the precision medicine era. Drugs targeting specific mutations, biomarker-driven patient selection, and adaptive trial designs all gained traction in blood cancers before they became standard in solid tumors. The commercial models had to evolve alongside the science.

Stelios Tzellos moved from GlobalData to IQVIA, where he continued working in oncology disease insights and the Analytics Center of Excellence. At IQVIA, he worked with pharmaceutical clients on forecasting and commercial planning across both haematology and solid tumor markets. The clients who performed best were the ones who applied lessons from haematology to their broader oncology portfolios.

Those lessons included building forecasts around biomarker prevalence rather than total diagnosis rates, modelling treatment sequencing as a dynamic rather than static process, and accounting for the impact of combination therapies on market share distribution. These are standard practices now. A decade ago, they were considered overly complex.

The Shift Inside AstraZeneca

Tzellos joined AstraZeneca in 2020 and has since held roles in business insights, analytics, and oncology marketing. AstraZeneca's oncology portfolio spans both solid tumors and haematological malignancies, and managing that portfolio requires a view across both domains.

The cross-functional work Tzellos leads at AstraZeneca reflects the same principle that haematology taught the industry: you can't forecast or plan in isolation. Product strategy, market access, and medical affairs all need to work from the same understanding of the disease environment. When they don't, launches underperform and portfolio decisions get made on incomplete information.

Where the Market Is Heading

The haematology market is still evolving. Next-generation CAR-T approaches, off-the-shelf cell therapies, and novel bispecifics are all in various stages of development. For pharmaceutical companies, that means the competitive dynamics that made haematology difficult to forecast a decade ago have only intensified.

Stelios Tzellos has worked at the intersection of these markets throughout his career. His academic training in molecular biology at Imperial College London gave him the foundation to understand the science. His consulting work at GlobalData and IQVIA gave him the commercial lens. And his current role at AstraZeneca gives him the perspective of someone who has to make decisions based on those forecasts, not just produce them.

Haematology didn't just change the treatment options for patients with blood cancers. It changed how the entire pharmaceutical industry thinks about market complexity, competitive intelligence, and commercial planning. The companies that figured that out early are the ones winning now.